227 related articles for article (PubMed ID: 20639307)
1. Clinical use of combined positron emission tomography and computed tomography in thymoma recurrence.
El-Bawab HY; Abouzied MM; Rafay MA; Hajjar WM; Saleh WM; Alkattan KM
Interact Cardiovasc Thorac Surg; 2010 Oct; 11(4):395-9. PubMed ID: 20639307
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
[TBL] [Abstract][Full Text] [Related]
5. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
6. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.
Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW
J Craniomaxillofac Surg; 2006 Jan; 34(1):9-16. PubMed ID: 16343913
[TBL] [Abstract][Full Text] [Related]
7. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
[TBL] [Abstract][Full Text] [Related]
8. Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology.
El-Bawab H; Al-Sugair AA; Rafay M; Hajjar W; Mahdy M; Al-Kattan K
Eur J Cardiothorac Surg; 2007 Apr; 31(4):731-6. PubMed ID: 17293120
[TBL] [Abstract][Full Text] [Related]
9. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of (18)F-FDG PET/CT in postoperative monitoring for patients with colorectal carcinoma.
Han A; Xue J; Zhu D; Zheng J; Yue J; Yu J
Cancer Epidemiol; 2011 Oct; 35(5):497-500. PubMed ID: 21296635
[TBL] [Abstract][Full Text] [Related]
11. First description of the role of ¹⁸F-FDG-PET/CT as compared to CT, MRI to suspect a case of thymoma in a pediatric patient.
Tsuchida T; Kinoshita S; Kawakita A; Yasutomi M; Tanizawa A; Kimura H
Hell J Nucl Med; 2012; 15(1):68-9. PubMed ID: 22413119
[No Abstract] [Full Text] [Related]
12. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
13. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
14. Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas.
Kao YH; Saad U; Tan AE; Magsombol BM; Padhy AK
Acta Radiol; 2011 May; 52(4):463-6. PubMed ID: 21498277
[TBL] [Abstract][Full Text] [Related]
15. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer.
Pan HS; Lee SL; Huang LW; Chen YK
Arch Gynecol Obstet; 2011 Feb; 283(2):335-41. PubMed ID: 20221620
[TBL] [Abstract][Full Text] [Related]
16. Recurrent thymoma: radiological (CT and FDG-PET) and histological (WHO criteria) features.
Ito H; Shimada K; Isogami K; Kondo T; Kaneta T; Takahashi S; Fukuda H
Radiat Med; 2006 May; 24(4):292-6. PubMed ID: 16958404
[TBL] [Abstract][Full Text] [Related]
17. Thymoma and immunodeficiency: (18)F-FDG-PET/CT imaging of Good syndrome.
Kelly A; Merlin C; Trouillier S; Cachin F; Guettrot-Imbert G
Hell J Nucl Med; 2013; 16(2):140-1. PubMed ID: 23687646
[No Abstract] [Full Text] [Related]
18. Role of FDG PET/CT in staging of recurrent ovarian cancer.
Son H; Khan SM; Rahaman J; Cameron KL; Prasad-Hayes M; Chuang L; Machac J; Heiba S; Kostakoglu L
Radiographics; 2011; 31(2):569-83. PubMed ID: 21415197
[TBL] [Abstract][Full Text] [Related]
19. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
Nasu K; Abe W; Takai N; Tomonari K; Narahara H
Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
[TBL] [Abstract][Full Text] [Related]
20. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report.
Liu RS; Yeh SH; Huang MH; Wang LS; Chu LS; Chang CP; Chu YK; Wu LC
Eur J Nucl Med; 1995 Dec; 22(12):1402-7. PubMed ID: 8586085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
